As previously reported, Wedbush initiated coverage of Zura Bio with an Outperform rating and $15 price target. The firm sees a favorable near- and long-term setup with shares likely to appreciate through 2026 as the market anticipates the first readout for an IL-17 combination candidate in hidradenitis suppurativa, followed by de-risked clinical readouts in the next 12-18 months.
